- Home
- GNPX vs PSTV Comparison
GNPX vs PSTV Comparison
Compare GNPX & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- PSTV
- Stock Information
- Founded
- GNPX 2009
- PSTV 1996
- Country
- GNPX United States
- PSTV United States
- Employees
- GNPX N/A
- PSTV N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- PSTV Medical/Dental Instruments
- Sector
- GNPX Health Care
- PSTV Health Care
- Exchange
- GNPX Nasdaq
- PSTV Nasdaq
- Market Cap
- GNPX 6.1M
- PSTV 6.3M
- IPO Year
- GNPX 2018
- PSTV N/A
- Fundamental
- Price
- GNPX $0.75
- PSTV $1.22
- Analyst Decision
- GNPX Strong Buy
- PSTV Strong Buy
- Analyst Count
- GNPX 1
- PSTV 2
- Target Price
- GNPX $10.00
- PSTV $13.50
- AVG Volume (30 Days)
- GNPX 367.1K
- PSTV 34.6K
- Earning Date
- GNPX 11-13-2024
- PSTV 03-04-2025
- Dividend Yield
- GNPX N/A
- PSTV N/A
- EPS Growth
- GNPX N/A
- PSTV N/A
- EPS
- GNPX N/A
- PSTV N/A
- Revenue
- GNPX N/A
- PSTV $5,725,000.00
- Revenue This Year
- GNPX N/A
- PSTV $32.12
- Revenue Next Year
- GNPX N/A
- PSTV N/A
- P/E Ratio
- GNPX N/A
- PSTV N/A
- Revenue Growth
- GNPX N/A
- PSTV 52.63
- 52 Week Low
- GNPX $0.28
- PSTV $0.93
- 52 Week High
- GNPX $13.00
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- GNPX 40.74
- PSTV 52.68
- Support Level
- GNPX $0.66
- PSTV $1.16
- Resistance Level
- GNPX $0.74
- PSTV $1.24
- Average True Range (ATR)
- GNPX 0.06
- PSTV 0.08
- MACD
- GNPX 0.00
- PSTV 0.01
- Stochastic Oscillator
- GNPX 35.04
- PSTV 48.00
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).